Risankizumab is a monoclonal antibody used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. In this test-specific episode of the "Answers From the Lab" podcast, Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new risankizumab assay (Mayo ID: RISA) measures the drug's concentration in blood to guide optimal patient treatment.

"Therapeutic drug monitoring is routinely used to assess loss of response to therapy and proactively manage patients taking biologics. It has become standard of care in Crohn's disease," Dr. Willrich says. "But anyone taking risankizumab for any condition could be recommended to have this test."

The mass spectrometry-based test can quantify risankizumab from 1 to 100 micrograms per milliliter in serum samples. "That's expected to cover trough and peak concentrations expected in all the conditions that risankizumab is prescribed for," Dr. Willrich says. Additional testing for risankizumab antibodies is under development.

"If patients do not meet therapeutic drug concentrations, providers can decide to personalize the treatment regimen or discontinue the drug," Dr. Willrich says.

Listen to learn more about Mayo Clinic Laboratories' new risankizumab assay.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

RISA   | Risankizumab, Serum

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less